MedTrace Logo

Within Subject Crossover Study of Cognitive Effects of Neflamapimod in Early-Stage Huntington Disease

NCT03980938 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2022-04-06

Study results available
· View outcomes & findings →

Summary

This is a double-blind, placebo-controlled 2-period 10-week treatment within-subject crossover study of neflamapimod in early-stage Huntington disease (HD). The primary objective is to determine whether neflamapimod can reverse hippocampal dysfunction in patients with early-stage HD, as assessed by the virtual water-maze-test for evaluating spatial learning and selected tests on the Cambridge Neuropsychological Test Automated Battery (CANTAB).

Conditions

  • Huntington Disease

Interventions

DRUG

neflamapimod

40 mg neflamapimod capsule

OTHER

Placebo

matching placebo capsule

Sponsors & Collaborators

  • Voisin Consulting, Inc.

    collaborator INDUSTRY

  • EIP Pharma Inc

    lead INDUSTRY

Principal Investigators

  • John Alam, MD · EIP Pharma

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
30 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-08
Primary Completion
2020-10-15
Completion
2020-10-15
FDA Drug
Yes

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03980938 on ClinicalTrials.gov